According to the Zhitong Finance APP, Sihuan Pharm (00460) rose nearly 4%, as of press time, it increased by 3.7% to HKD 0.56, with a turnover of HKD 2.048 million.

In terms of news, Sihuan Pharm announced that Simcere of its non-wholly-owned subsidiary had applied for clinical trials (IND application) for Simcereglutide injection for overweight or obesity (collectively referred to as "weight loss"), which has been accepted by China's National Medical Products Administration.

By 2023, the global total sales of Simcereglutide have exceeded 20 billion US dollars, of which the sales of Simcereglutide injection for weight loss are about 4.5 billion US dollars, a year-on-year increase of more than 400% in 2022, showing an explosive growth.